Table 3.
Isoflavonoids in plasma and urine in the placebo and intervention groups and correlations with compliance to study product
| Isoflavone Values |
Isoflavone Values versus Stud Product Doses¶ |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Placebo |
Soy |
P-value* |
Placebo |
Soy |
||||||
| Baseline | End | Baseline | End | Baseline | End | r | P | r | P | |
| PL † | ||||||||||
| DE | 62 ± 131 | 79 ± 249 | 52 ± 113 | 400 ± 510 | 0.78 | <.0001 | 0.11 | 0.21 | 0.40 | <.0001 |
| GE | 63 ± 161 | 64 ± 151 | 53 ± 103 | 517 ± 577 | 0.11 | <.0001 | 0.04 | 0.62 | 0.44 | <.0001 |
| GLYE | 5.2 ± 12 | 8.4 ± 32 | 5.8 ± 11 | 16 ± 29 | 0.93 | <.0001 | 0.15 | 0.07 | 0.37 | <.0001 |
| EQ | 13 ± 55 | 25 ± 72 | 9.8 ± 24 | 129 ± 232 | 0.25 | 0.0008 | 0.03 | 0.70 | 0.17 | 0.03 |
| DMA | 22 ± 59 | 31 ± 64 | 23 ± 70 | 214 ± 283 | 0.70 | <.0001 | 0.13 | 0.11 | 0.31 | .0001 |
| DHDE | 23 ± 75 | 38 ± 184 | 18 ± 43 | 120 ± 224 | 0.76 | <.0001 | 0.10 | 0.23 | 0.30 | .0001 |
| DHGE | 6.8 ± 30 | 14 ± 100 | 5.8 ± 16 | 27 ± 88 | 0.71 | <.0001 | 0.08 | 0.31 | 0.21 | 0.009 |
| OU ‡ | ||||||||||
| DE | 4.2 ± 9.6 | 3.8 ± 9.2 | 3.7 ± 7.7 | 25 ± 25 | 0.45 | <.0001 | −0.03 | 0.74 | 0.46 | <.0001 |
| GE | 1.6 ± 5.7 | 1.5 ± 5.2 | 1.4 ± 3.0 | 13 ± 14 | 0.22 | <.0001 | 0.01 | 0.94 | 0.47 | <.0001 |
| GLYE | 0.6 ± 1.5 | 0.5 ± 1.2 | 0.5 ± 1.0 | 2.3 ± 2.6 | 0.34 | <.0001 | −0.04 | 0.64 | 0.45 | <.0001 |
| EQ | 0.9 ± 5.1 | 1.4 ± 6.0 | 0.5 ± 1.7 | 9.6 ± 18 | 0.77 | 0.21 | −0.12 | 0.13 | 0.16 | 0.05 |
| DMA | 1.4 ± 3.0 | 1.1 ± 3.0 | 1.4 ± 3.4 | 12 ± 13 | 0.57 | <.0001 | 0.00 | 0.96 | 0.34 | <.0001 |
| DHDE | 2.3 ± 6.9 | 1.7 ± 4.9 | 1.8 ± 4.0 | 11 ± 14 | 0.69 | <.0001 | 0.00 | 0.97 | 0.32 | .0001 |
| DHGE | 0.9 ± 4.6 | 0.6 ± 2.4 | 0.8 ± 2.8 | 3.9 ± 9.3 | 0.10 | <.0001 | 0.02 | 0.81 | 0.23 | 0.004 |
| SU § | ||||||||||
| DE | 3.3 ± 9.4 | 5 ± 15 | 3.0 ± 6.7 | 16 ± 20 | 0.36 | <.0001 | −0.10 | 0.22 | 0.47 | <.0001 |
| GE | 1.3 ± 3.8 | 2.7 ± 13 | 1.2 ± 3.0 | 8.0 ± 9.7 | 0.23 | <.0001 | −0.06 | 0.45 | 0.45 | <.0001 |
| GLYE | 0.4 ± 1.3 | 0.4 ± 1.0 | 0.4 ± 1.5 | 1.2 ± 1.6 | 0.51 | <.0001 | −0.05 | 0.52 | 0.40 | <.0001 |
| EQ | 0.6 ± 3.9 | 1.3 ± 6.3 | 0.6 ± 2.4 | 10 ± 21 | 0.25 | 0.02 | −0.11 | 0.19 | 0.17 | 0.03 |
| DMA | 1.5 ± 3.8 | 2.3 ± 6.9 | 1.7 ± 4.0 | 11 ± 12 | 0.61 | <.0001 | −0.03 | 0.69 | 0.35 | <.0001 |
| DHDE | 1.8 ± 4.9 | 3.2 ± 13 | 2.1 ± 4.8 | 9.7 ± 14 | 0.40 | <.0001 | −0.05 | 0.52 | 0.35 | <.0001 |
| DHGE | 0.6 ± 2.2 | 3.2 ± 22 | 0.9 ± 3.1 | 3.6 ± 12 | 0.10 | 0.001 | −0.06 | 0.50 | 0.24 | 0.002 |
Wilcoxon rank sum test comparing placebo to soy group
Plasma mean ± SD in nM; baseline n= 175 placebo+175 soy subjects; Study End n=136 placebo+143 soy subjects
Overnight urine mean ± SD in nmol/mg creatinine; baseline n= 172 placebo+170 soy subjects; Study End n=120 placebo+126 soy subjects
Spot urine mean ± SD in nmol/mg creatinine; baseline n= 174 placebo, 175 active; Study End n = 135 placebo, 143 soy subjects
Comparing inter-individually logged isoflavone values with percentage of ideally consumed soy protein doses (bars or protein packages) determined at each specimen collection visit; r=Pearson correlations; P = t-test value; 653 (PL), 618(OU, and 643 (SU) data pairs in the placebo group from 146 subjects; 721 (PL), 673 (OU) and 714 (SU) data pairs in the soy group from 154 subjects
Abbreviations: PL= plasma, OU=overnight urine, SU= spot urine, DE= daidzein, GE= genistein, GLYE= glycitein, EQ= equol, DMA= O-desmethylangolensin, DHDE= dihydrodaidzein, DHGE= dihydrogenistein